Work

AB-101, an allogeneic, non–genetically modified, natural killer (NK) cell therapy, evaluated as monotherapy or in combination with rituximab in R/R non-Hodgkin lymphoma.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.7529

Authors: Rashmi Khanal, Amitkumar Mehta, Joseph J. Maly, Houston Holmes, Jennifer N. Saultz, Ayad Hamdan, Anne M. Robinson, Mili Mandal, Aakash Patel, Thorsten Graef, Anita G. Seto, Umar Farooq

Institutions: Fox Chase Cancer Center, University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center, Norton Healthcare, Texas Oncology, Oregon Health & Science University, University of California San Diego Medical Center, University of Iowa Hospitals and Clinics

Language: English

Topic: Immune Cell Function and Interaction

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4379283440

Cites:

Cited by: 4

Related to: 10